Skip to main content
. 2023 May 1;133(9):e161929. doi: 10.1172/JCI161929

Figure 1. Aurora A kinase inhibitor elevates PD-L1 expression in tumor cells.

Figure 1

(A) Flow cytometric analysis of cell-surface PD-L1 expression in BxPC3 cells following treatment for 72 hours with 1 μmol/L alisertib, 0.5 μmol/L AZD1152, or 0.5 μmol/L tozasertib. (B) Normalized MFI for the data shown in A (n = 3). (C) Western blot showing PD-L1 expression in BxPC3 cells after treatment for 72 hours with the indicated concentrations of alisertib. (D and E) qRT-PCR analysis of PDL1 expression in BxPC3 cells after treatment with alisertib at the indicated concentrations (D) and for the indicated durations (E) (n = 3). (F) Flow cytometric analysis of cell-surface PD-1 binding of BxPC3 cells after treatment for 72 hours with the indicated concentrations of alisertib. (G) Normalized MFI for the data in F (n = 3). hFc, human Fc. Data indicate the mean ± SD. **P < 0.01 and ****P < 0.0001, by 1-way ANOVA.